Recurrent Disease Completed Phase 1 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00383474Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseTreatment